Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for Krystal Biotech (KRYS) over the last 3 years, with Q3 2025 value amounting to $4.3 million.

  • Krystal Biotech's Cost of Revenue fell 3622.08% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 1902.91%. This contributed to the annual value of $20.1 million for FY2024, which is 54838.4% up from last year.
  • As of Q3 2025, Krystal Biotech's Cost of Revenue stood at $4.3 million, which was down 3622.08% from $7.2 million recorded in Q2 2025.
  • Krystal Biotech's Cost of Revenue's 5-year high stood at $7.2 million during Q2 2025, with a 5-year trough of $223000.0 in Q3 2023.
  • Moreover, its 3-year median value for Cost of Revenue was $4.9 million (2024), whereas its average is $4.4 million.
  • Per our database at Business Quant, Krystal Biotech's Cost of Revenue skyrocketed by 289730.94% in 2024 and then tumbled by 3622.08% in 2025.
  • Quarter analysis of 3 years shows Krystal Biotech's Cost of Revenue stood at $2.9 million in 2023, then surged by 72.38% to $4.9 million in 2024, then decreased by 13.86% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $7.2 million for Q2 2025, and $5.0 million during Q1 2025.